Plasma galectin-9 is associated with clinical disease activity in treatment naïve early rheumatoid arthritis, unaffected by D-mard treatment, and in vitro modulates the secretion of MCP-1 and IL-6 in rheumatoid arthritis synovial fibroblasts

Morten Aagaard Nielsen, Ditte Køster, K Stengaard-Petersen, Pierre Busson, K Hørslev-Petersen, Merete Lund Hetland, Mikkel Østergaard, M Hvid, Tue W Kragstrup

Abstract

Background: Fibroblast-like synoviocytes (FLS) are pivotal mediators of rheumatoid synovitis expansive growth and invasiveness which respond insufficiently to disease-modifying antirheumatic drugs. Galectin-9 (Gal-9) is a lectin with well-conserved carbohydrate-recognition domains. Gal-9 has been reported to have both pro- and anti-inflammatory properties based on its ability to modulate RA FLS. Gal-9 levels are elevated in serum of rheumatoid arthritis (RA) patients, and high levels of Gal-9 have been identified in both the synovial fluid and in the inflamed synovial tissue of patients with RA.
OriginalsprogEngelsk
Publikationsdato2022
StatusUdgivet - 2022
BegivenhedEULAR 2022 - Copenhagen
Varighed: 1 jun. 20224 jun. 2022

Konference

KonferenceEULAR 2022
ByCopenhagen
Periode01/06/202204/06/2022

Citationsformater